Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: ubiquitin modulators - Progenra

Next Previous
Drug Profile

Research programme: ubiquitin modulators - Progenra

Alternative Names: Cbl-b inhibitors - Progenra; Deubiquitylating enzyme inhibitors - Progenra; MuRF1 inhibitors - Progenra; P 013222; P 022077; P 13222; P 5091; P005091; P1001; P1002; P1003; Synoviolin/Hrd1 inhibitors - Progenra; ubiquitin isopeptidase inhibitors - Progenra; USP2 inhibitors - Progenra; USP47 inhibitors - Progenra; USP7 inhibitors - Progenra

Latest Information Update: 04 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Progenra
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Small molecules
  • Mechanism of Action CBLB protein expression inhibitors; Endopeptidase inhibitors; Ubiquitin-protein ligase inhibitors; USP2 protein inhibitors; USP47 protein inhibitors; USP7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Asthma; Cancer; Psoriasis
  • No development reported Multiple myeloma; Muscular atrophy; Rheumatoid arthritis

Most Recent Events

  • 28 Nov 2023 Preclinical trials in Asthma in USA (unspecified route) (Progenra website; November 2023)
  • 28 Nov 2023 Preclinical trials in Psoriasis in USA (unspecified route) (Progenra website; November 2023)
  • 28 Nov 2023 Preclinical development is ongoing in Cancer in USA (Progenra website; November 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top